Evidence map›Paper›PMID 35324255›Full record

ArticleJCO global oncology2022

Outcomes of Cervical Cancer in HIV-Positive Women Treated With Radiotherapy at a Tertiary Care Center in India.

Lavanya Gurram, Samarpita Mohanty, Supriya Chopra, Surbhi Grover, Reena Engineer, Sudeep Gupta, Jaya Ghosh, Seema Gulia, Sheela Sawant, Anuprita Daddi and 6 more

Open access · goldAbstract read
In one paragraph

Article in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Lavanya GurramDepartment of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-3460-6604
Samarpita MohantyDepartment of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-8037-957X
Supriya ChopraDepartment of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-2656-1792
Surbhi GroverDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-7443-5937
Reena EngineerDepartment of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Sudeep GuptaAdvanced Centre for Training, Research Education in Cancer, Navi Mumbai, India.ORCID 0000-0002-6742-6378
Jaya GhoshDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0001-6670-1772
Seema GuliaDepartment of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Sheela SawantDepartment of Medicine, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Anuprita DaddiDepartment of Medicine, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Kedar DeodharDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Santosh MenonDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Bharat RekhiDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-3509-4794
T S ShylasreeDepartment of Gynecologic Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Amita MaheshwariDepartment of Gynecologic Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0001-7655-1608
Umesh MahantshettyHomi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, India.
Homi Bhabha National Institute · INAdvanced Centre for Treatment, Research and Education in Cancer · INCancer Hospital and Research Institute · INUniversity of Pennsylvania · US

Funding

Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrenceK08CA230170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GROVER, SURBHI · 2019 to 2023
$1.4M
NCI NIH HHS K08 CA230170
6 · The paper itself

Abstract

purposeThere are limited data on management of cervical cancer in women living with HIV in the modern antiretroviral therapy era. The study aimed to evaluate outcomes and toxicities of these patients treated with radiotherapy. MATERIALS AND

methodsA retrospective analysis of HIV-positive cervical cancer patients treated with radiotherapy between 2011 and 2018 was conducted at a tertiary care center in India.

resultsEighty-two HIV-positive cervical cancer patients treated with radiotherapy were identified. Their median age was 45 years. Seventy-four (90%) patients received radiotherapy with curative-intent and eight patients received palliative radiotherapy. Median CD4 count at the start of treatment was 342 cells/mm

conclusionStandard treatment of chemoradiation should be planned in women living with HIV with well-managed HIV presenting with locally advanced cervical cancer. Our study highlights the need for optimal management of these patients by a multidisciplinary team with intensive supportive care to ensure completion of planned treatment to achieve better outcomes.

Indexed as

Antineoplastic AgentsUterine Cervical NeoplasmsCisplatinFemaleHumansMiddle AgedRetrospective StudiesTertiary Care CentersAntineoplastic AgentsCisplatin

Identifiers

PMID35324255
PMCPMC9071252
OpenAlexW4220958439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.